Abbott Laboratories

New York Stock Exchange
Back to all articles
Very Bearish -85

Abbott Laboratories must pay at least $53 million in cases over infant formula, jury decides

AI-generated analysis

📉 A Cook County jury ordered Abbott Laboratories to pay at least $53 million in compensatory damages in four infant formula cases.

👶 The verdict involves Chicago-area babies who developed necrotizing enterocolitis (NEC) after consuming Abbott's formula for premature infants.

⚖️ The jury found Abbott liable on three counts: defective design, failure to warn of dangers, and negligence.

💰 Two children will receive $15 million, one will receive $16 million, and the fourth will receive $7 million in compensatory damages.

📅 Four more cases with mothers Antonia Mendez, Casie Thompson, Kara Sharpe, and Eboni Williams were decided after a monthlong trial.

⚠️ Abbott maintains that its formula does not cause NEC, citing an FDA/CDC/NIH report linking NEC risk to the absence of human milk rather than formula exposure.

⛔ CEO previously warned they could pull preterm infant formula if litigation continues, raising concerns among doctors about nutritional options.

🏥 The four cases are among more than 1,700 Abbott faces over the issue across the country, with these being the first state court trials in Illinois.

💬 Judge John Ehrlich stated Abbott should have included warning labels on its formula and criticized testimony suggesting it was cruel to warn parents about risks.

🔎 This verdict adds to prior legal outcomes, including a $495 million verdict against Abbott and one win for the company in previous state trials.

📢 Punitive damages will be decided when the jury reconvenes Friday to determine if further penalties are warranted against the company.

Bullish Signals
  • Abbott maintains that available evidence supports the hypothesis that the absence of human milk rather than formula exposure is associated with an increase in NEC risk, citing 2024 statements from the FDA, CDC, and NIH.
  • The American Academy of Pediatrics released a clinical report this year confirming that preterm infant formula is recommended when a mother's own milk and donated breast milk are not available.
  • Legal arguments presented suggest that infants would have developed NEC regardless of what they were fed due to other conditions such as prematurity and antibiotic use.
  • Abbott's CEO previously indicated the company values its formula, noting it serves as a 'critical' product for NICUs across the country.
  • Research acknowledges an association between cow's milk-based formulas and higher NEC rates but does not establish causation, distinguishing between association and cause-effect relationships.
  • Expert testimony highlighted that this product is essential as the last line of defense for premature infants when breast milk isn't available.
  • The Cook County trial was a first-of-its-kind state court proceeding in Illinois regarding these specific cases, offering guidance on potential resolutions for ongoing litigation.
Risk Factors
  • Abbott Laboratories was ordered to pay at least $53 million in compensatory damages for four cases involving dangerous intestinal disease (necrotizing enterocolitis) in Chicago-area babies who consumed the company's formula between 2012 and 2019.
  • A Cook County jury found Abbott liable for defectively designed formula, inadequate warnings about dangers, and negligence in three counts for each child, with one spokesperson not providing comment on the verdict by deadline.
  • The verdict is part of over 1,700 lawsuits Abbott faces across the country regarding whether its specialized formula causes necrotizing enterocolitis (NEC), a disease often fatal in premature babies.
  • Abbott previously suggested it could pull its formula for preterm infants if continued litigation forces the move, raising concerns among doctors about fewer nutritional options available to premature babies.
  • Judge John Ehrlich criticized Abbott's labeling practices, stating the company should have included a warning on its label because it knew there was a substantial risk of NEC associated with its formula.
  • Legal counsel Karis argued that a warning label wouldn't have made a difference as parents defer to doctors in hospitals, while Judge Ehrlich called testimony claiming it would be cruel to inform parents of the risk 'nothing short of astounding'.
  • The Cook County cases are bellwether trials for hundreds of similar cases filed in federal court in Chicago, with past trials resulting in a $495 million verdict against Abbott and one win for the company.
Full Analysis
Abbott Laboratories was ordered by a Cook County jury on Thursday evening to pay at least $53 million in compensatory damages in four separate cases involving Chicago-area babies who developed necrotizing enterocolitis (NEC) after consuming the company's formula for premature infants. After more than a month of trial and just over a day of deliberations, the jury ruled Abbott liable on three counts per child: defectively designed product, failure to warn about dangers and risks, and negligence. The verdict allocates specific compensation amounts among the four plaintiffs, with Antonia Mendez's son receiving $15 million, Casie Thompson's daughter receiving $16 million, Kara Sharpe's child receiving $16 million, and Eboni Williams' infant receiving $7 million for pain, suffering, and loss of a normal life. The mothers and attorneys declined to comment immediately after the decision, though Eboni Williams was visibly emotional during the reading of the verdict in court. The upcoming Friday session will see the jury reconvene to determine additional punitive damages that Abbott must pay, separate from the compensatory awards. This ruling marks another significant setback for Abbott in its ongoing legal battle over whether its specialized formula causes NEC, a potentially fatal condition where the intestinal lining becomes inflamed and dies. While Abbott maintains its formula does not cause NEC and cites a 2024 joint statement from the FDA, CDC, and NIH suggesting the absence of human milk is associated with higher NEC risk rather than formula exposure itself, Abbott executives have previously indicated they might withdraw their preterm infant formula entirely if litigation continues—a move that could limit nutritional options for premature infants. The four cases decided Thursday were among more than 1,700 lawsuits Abbott faces nationwide regarding the issue and were the first to go to trial in Illinois state court. Prior trials on the same issue resulted in a $495 million verdict against Abbott in one instance and a win for the company in another. During the trial, defense attorney Hariklia Karis argued that conditions such as prematurity and antibiotic use led to NEC regardless of feeding method, while plaintiff attorney Sean Grimsley insisted the formula was harmful and contributed to all four cases, urging it should be only the last resort after mother's or donated breast milk is unavailable. Cook County Circuit Court Judge John Ehrlich criticized Abbott for allegedly knowing the substantial risk of NEC associated with its formula and noted that a warning on the label could have been appropriate given this knowledge. Hundreds of similar cases remain pending in federal court, with four designated as bellwether trials to guide outcomes for the broader litigation.